Oxygen Level and Safe Emergence From Anesthesia
This study is currently recruiting participants.
Verified April 2013 by Landstinget Västmanland
Sponsor:
Landstinget Västmanland
Information provided by (Responsible Party):
Lennart Edmark, Landstinget Västmanland
ClinicalTrials.gov Identifier:
NCT01779076
First received: January 28, 2013
Last updated: April 25, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Using a protective ventilation strategy during general anesthesia from pre-oxygenation to emergence and selecting patients without risk of a difficult airway or intubation, a lower fraction of inspiratory oxygen (FIO2) can be used during extubation. This might reduce the postoperative area of atelectasis without desaturations becoming more common.
| Condition | Intervention |
|---|---|
|
Focus of Study is Postoperative Pulmonary Atelectacis |
Procedure: 30% oxygen Procedure: 100% oxygen |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention |
| Official Title: | Emergence From General Anesthesia With Laryngeal Mask Airway and Increased End-expiratory Pressure Using 30% Oxygen is as Safe as With 100% Oxygen But Reduces the Area of Post Operative Atelectasis. |
Resource links provided by NLM:
Further study details as provided by Landstinget Västmanland:
Primary Outcome Measures:
- Area of atelectasis [ Time Frame: 30 minutes ] [ Designated as safety issue: Yes ]The area of atelectasis is investigated by computed tomography of the lungs postoperatively
Secondary Outcome Measures:
- Peripheral oxygen saturation (SpO2) [ Time Frame: 3 hours ] [ Designated as safety issue: Yes ]SpO2 is continuously assessed postoperatively.
| Estimated Enrollment: | 60 |
| Study Start Date: | February 2013 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 100% oxygen during extubation
In this arm the intervention will consist of 100 % oxygen.
|
Procedure: 100% oxygen |
|
Experimental: 30% oxygen during extubation
In this arm the intervention will consist of 30 % oxygen.
|
Procedure: 30% oxygen |
Eligibility| Ages Eligible for Study: | 30 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- No sign of difficult airway or intubation
- Day case surgery in total intravenous anesthesia with laryngeal mask airway without adding regional anesthesia of plexus brachialis or muscle relaxant.
- Body mass index less than 35.
- American Society of Anesthesiologists physical status (ASA) class I-III
Exclusion Criteria:
- Body mass index 35 or higher
- Increased risk of aspiration
- Obstructive sleep apnea syndrome
- Procedures during surgery making a former easy airway a difficult airway
- Need for opioids after extubation
- Hypothermia
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01779076
Contacts
| Contact: Lennart Edmark, M.D. | 21 173000 ext 046 | lennart.edmark@ltv.se |
Locations
| Sweden | |
| Västmanlands sjukhus Köping | Recruiting |
| Köping, Västmanland, Sweden, 731 81 | |
| Sub-Investigator: Lennart Edmark, M.D. | |
Sponsors and Collaborators
Landstinget Västmanland
Investigators
| Principal Investigator: | Mats Enlund, M.D., Ph.D. | Landstinget i Värmland |
More Information
No publications provided
| Responsible Party: | Lennart Edmark, M.D., Landstinget Västmanland |
| ClinicalTrials.gov Identifier: | NCT01779076 History of Changes |
| Other Study ID Numbers: | Dnr 2012 / 539 |
| Study First Received: | January 28, 2013 |
| Last Updated: | April 25, 2013 |
| Health Authority: | Sweden: Regional Ethical Review Board |
Additional relevant MeSH terms:
|
Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 22, 2013